SCHEMBL2297633

SCHEMBL2297633

Cc1ccc(COC([NH])=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.49
MMP12 P39900 2/20 0.49
MMP1 P03956 1/20 0.49
MMP9 P14780 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
AGXT P21549 2/20 0.48
MAOB P27338 2/20 0.47
P2RX4 Q99571 1/20 0.46
PARP10 Q53GL7 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
LMNA P02545 1/20 0.45
NAAA Q02083 1/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646548 0.83 AGXT (0.52) MMP2MMP12MMP1MMP9NPC1
SCHEMBL26555 0.83 AGXT (0.52) MMP2MMP12MMP1MMP9NPC1
SCHEMBL14383883 0.81 MMP2 (0.50) MMP2MMP12MMP1MMP9NPC1
SCHEMBL873414 0.81 ALDH1A1 (0.67) MMP2MMP12MMP1MMP9NPC1
SCHEMBL5369370 0.81 ALDH1A1 (0.50) MMP2MMP12MMP1MMP9NPC1
P-Xylene SCHEMBL9685877 0.81 ALDH1A1 (0.67) MMP2MMP12MMP1MMP9NPC1
SCHEMBL11479085 0.81 MMP2 (0.50) MMP2MMP12MMP1MMP9NPC1
SCHEMBL1565585 0.80 ALDH1A1 (0.57) MMP2MMP12MMP1MMP9NPC1
SCHEMBL6556972 0.79 ALDH1A1 (0.64) MMP2MMP12MMP1MMP9NPC1
SCHEMBL6176885 0.79 KMT2A (0.54) MMP1MAOBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-04 US disclosed
US-RE39420-E1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-12-05 US disclosed
EP-0826673-B1 ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO (JP) 2002-11-20 EP disclosed
US-5972946-A NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1999-10-26 US disclosed
US-5908858-A OSTEOPOROSIS; LEUKOTRIENE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1999-06-01 US disclosed
EP-0826673-A1 ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1998-03-04 EP disclosed
EP-0799823-A1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1997-10-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate REN, PKD1, KCNT1 MMP2 2487/4885MMP12 3126/4885MMP1 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.